Summary
ABPP (2-amino-5-bromo-6-phenyl-4-pyrimidinone) is a pyrimidinone with known interferon-inducing, natural killer (NK) cell activity enhancing, antiviral and antitumor properties in several animal species. Its effect on CC531, a dimethylhydrazine-induced, transplantable, weakly immunogenic adenocarcinoma of the colon in WAG rats, was studied. ABPP was found to have no direct cytotoxic effect on CC531 cells in vitro. When small cubes of tumor of equal weight were implanted under the renal capsule, administration of 250 mg/kg of ABPP i. p. on day 0 and +1 led repeatedly to significant (p<0.02 up to p<0.001) inhibition of tumor growth, when measured on day +7. Lower doses or a single dose of ABPP did not achieve this effect. Late administration (on day +6 and +7) of 250 mg/kg of ABPP in this model was found to have no effect on tumor growth when measured on day +13. When 5×105 tumor cells were injected in the portal vein, administration of 250 mg/kg of ABPP i.p. on day 0 and +1 reduced significantly (p=0.002) the number of liver metastases, when counted on day +30. Survival in this group was significantly prolonged (p<0.01). However when ABPP was given on day +6 and +7, significantly more (p<0.02) metastases in the liver were counted on day +30. The results show a significant antitumor effect of ABPP against tumor CC531 in the subrenal capsule assay (SRCA) model as well as in the liver metastasis model when administered at the time of tumor inoculation. Late administration of ABPP did not inhibit tumor growth in the SRCA and significantly enhanced the development of liver metastases. The role of timing, tumor site, and the mechanisms by which this dual outcome of immunotherapy with ABPP is mediated are discussed. The results of these experiments may have important implications for the design of clinical studies with ABPP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antikatzides TG, Saba TM (1977) Kupffer cell clearance function following intravenous tumor cell challenge. J Reticuloendothel Soc 22:1–12
Colmerauer ME, Koziol JA, Pilch YS (1980) Enhancement of metastasis development by BCG immunotherapy. J Surg Oncol 15:235–241
Earhart RH, Hamilton RD, Henry CS, Hanover CK, Maile MH, Agrawal BL, Todd WM (1985) Phase I trial, pharmacokinetics and interferon (IFN) induction of an oral devided-dose schedule of 2-amino-5-bromo-6-phenyl-(3H)-pyrimidinone (ABPP) in cancer patients. Proc AACR 26:159
Eggermont AMM, Marquet RL, De Bruin RWF, Weimar W, Jeekel J (1986) Site-specific antitumor effects of 2 pyrimidinone compounds in rats. Br J Cancer in press
Hanna N, Fidler IJ (1980) Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 65:801–809
Huang K (1982) Modulation of phagocytosis. Texas Rep Biol Med 41:375–380
Hutchinson IV (1980) Antigen reactive cell opsonization (AR-CO) and its role in antibody mediated immune suppression. Immunol Rev 49:167–169
Ishibashi T, Yamada H, Harada S, Harada Y, Takamoto M, Sugiyama K (1978) Inhibition and promotion of tumor growth by BCG: evidence for stimulation of humoral enhancing factors by BCG. Int J Cancer 27:67–71
LI, LH, Wallace TL, Richard KA, Tracey DE (1985) Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia. Cancer Res 45:532–538
Lotzova E, Savary CA, Stringfellow DA (1983) 5-Halo-6-phenyl-pyrimidinones: new molecules with cancer therapeutic potential and interferon inducing capacity are strong inducers of murine natural killer cells. J Immunol 130:965–969
Marquet RL, Westbroek DL, Jeekel J (1984) Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 33:689–692
Milas L, Hersh AM, Stringfellow DA, Hunter N (1982) Studies on the antitumor activities of pyrimidinone-interferon inducers. I. Effect against artificial and spontaneous lung metastases of murine tumors. J Natl Cancer Inst 68:139–145
Prehn RT, Main JW (1957) Immunity to methylcholanthrene induced sarcomas. J Natl Cancer Inst 18:769–778
Proctor JW, Auclair BG, Lewis MG (1976) The effect of BCG on B16 mouse melanoma: a comparison of routes of administration on tumour growth and different anatomical site. Eur J Cancer 12:203–210
Reinhold H (1965) A cell dispersion technique for use in quantitative transplantation studies with solid tumors. Eur J Cancer 1:67–71
Riccardi C, Puccetti P, Santoni A, Herberman RB (1979) Rapid in vivo assay of mouse natural killer cell activity. J Natl Cancer Inst 63:1041–1045
Ryd W, Hagmar B, Lundgren E, Strannegard O (1979) Discrepant effects of interferon on murine syngeneic ascites tumors and their solid metastasizing counterparts. Int J. Cancer 23:397–401
Sakai A (1970) Role of the liver in kidney allograft rejection in the rat. Transplantation 9:333–334
Schatten S, Granstein RD, Debrin JA, Greene MI (1984) Suppressor T cells and the immune response to tumors. CRC, Crit Rev Immunol 44:335–379
Sidky YA, Borden EC, Wierenga W, Groveman DS, Bryan GT (1985) Antitumor effects of interferons (IFNs) and two IFN-inducing pyrimidinones. Proc AACR, 26:276
Stringfellow DA (1980) 6-Aryl pyrimidinones: Interferon inducers-immunoregulators-antiviral and antineoplastic agents. In: Hersh E, Chirigos M (eds) Augmenting agents in cancer therapy. Raven Press, New York, pp 215–229
Taggart MT, Loughman BE, Gibbons AJ, Stringfellow DA (1980) Immunomodulatory effects of 2-amino-5-bromo-4-phenyl-6-pyrimidinol and its isocytosine analogs. In: Nelson, Grassi (eds) Current chemotherapy and infectious diseases. Proceedings of the 11th Internation Congress of Chemotherapy. American Society for Microbiology, Washington D. C, pp 1400–1401
Vaage J (1983) Mammary tumor growth inhibition in C3H/He mice by long-term bacillus calmette-guerin immunoprophylaxis versus enhancement by primary bacillus calmette-guerin therapy. Cancer Res 43:577–5782
Vuitton D, Eloy R, Clendinnen G, Grenier JF (1977) Role of Kupffer Cells and Suppressor T cells in the graft versus host reaction after intrahepatic lymphoid tissue implantation. Cell Immunol 34:138–145
Author information
Authors and Affiliations
Additional information
This study was supported in part by a grant from The Upjohn Company, Kalamazoo, Michigan, USA
Rights and permissions
About this article
Cite this article
Eggermont, A.M.M., Marquet, R.L., de Bruin, R.W.F. et al. Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor site. Cancer Immunol Immunother 22, 217–220 (1986). https://doi.org/10.1007/BF00200036
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00200036